
zzso binds zzso at DNA minor zzso zzso DNA replication and zzso A phase I study was undertaken to investigate safety, zzso zzso zzso recommended phase II dose zzso zzso zzso and preliminary zzso activity of zzso as a zzso or zzso infusion zzso 

Patients with advanced solid zzso received zzso in a dose escalation trial, as guided by toxicity and zzso zzso 

A total of 47 patients were zzso 27 patients on the zzso schedule zzso zzso zzso and 20 patients on the zzso schedule zzso zzso zzso zzso zzso comprised zzso zzso zzso fatigue, elevated zzso and zzso establishing the zzso schedule zzso at zzso zzso zzso With the zzso schedule, zzso of zzso zzso and zzso established the zzso at zzso zzso zzso Common zzso adverse events at the zzso comprised grade 1-2 zzso fatigue and zzso In both schedules, zzso increased linearly, but doses over the zzso schedule zzso resulted in higher than zzso increases in zzso A patient with advanced zzso zzso had zzso shrinkage by zzso and three patients had zzso stable disease zzso zzso 

zzso is well zzso with preliminary evidence of zzso activity zzso The zzso zzso schedule is being assessed in phase II clinical zzso 

